Archive for Chemo Therapy Failure
UroToday.com published a dual-center study today that confirms that carboplatin and paclitaxel (a taxane product) has an active effect on PSA when used in the treatment of men with castrate resistant prostate cancer (CRPC) after docetaxel (chemotherapy for prostate cancer). Read More→
New Drug for Advanced Prostate Cancer
Posted by: | Comments
New Drug for Advanced Prostate Cancer
Docetaxel (Chemotherapy) Re-Treatment – Can It Work Again?
Posted by: | CommentsA group of researchers from the Dipartimento di Endocrinologia ed Oncologia Clinica e Molecolare, Università Federico II, Napoli, Italy wanted to know if retreatment with docetaxel could be tolerated and have a positive effect in men with castration-resistant prostate cancer (CRPC) who have already failed chemotherapy.
The researchers evaluated 45 men who had initially responded to docetaxel therapy and then had disease progression. The prospective multicenter study was conducted between November 2005 and January 2009. The men in the study were retreated with docetaxel (chemotherapy). Read More→
Sanofi-aventis, the pharmaceutical company that makes taxotere and the newly approved drug, Jevtana (cabazitaxel) yesterday announced that their newly approved treatment for men with metastatic hormone-refractory prostate cancer (mHRPC) who have been previously treated with a docetaxel-based treatment regimen and failed is finally available for distribution in the United States. Around one month ago, Jevtana was approved by the U.S. Food and Drug Administration (FDA), but it has not been available. Read More→
Prostate Cancer SATURN Trial, a Phase 3 Trial in Men with Metastatic Prostate Cancer
Posted by: | CommentsA new phase 3, registration trial has been announced by OncoGenex Pharmaceuticals, Inc. of its investigational drug custirsen sodium (OGX-011/TV-1011). The trial, for men with metastatic castrate resistant prostate cancer (mCRPC) is referred to as the Prostate Cancer SATURN Trial.
This randomized, controlled, trial will include approximately 50 cancer centers and is planned to enroll approximately 300 men with mCRPC who have previously responded to first-line docetaxel therapy, but subsequently have disease progression that involves prostate cancer-related pain despite opioid usage. Read More→
